Limberg Jessica, Ullmann Timothy M, Stefanova Dessislava, Finnerty Brendan M, Beninato Toni, Fahey Thomas J, Zarnegar Rasa
Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, 525 E. 68th St, F-2024, New York, NY, 10065, USA.
World J Surg. 2020 Feb;44(2):348-355. doi: 10.1007/s00268-019-05098-5.
Primary squamous cell carcinoma of the thyroid (ThySCC) is a rare cancer, primarily described only in case reports. We aimed to characterize the prognosis of ThySCC and compare its oncologic behavior to other thyroid malignancies.
The National Cancer Database was queried to identify patients with ThySCC, papillary, tall cell variant, poorly differentiated (PDTC), and anaplastic (ATC) subtypes of thyroid cancer treated from 2004 to 2015. Demographics, tumor characteristics, and treatments were compared by tumor type and assessed to identify independent predictors of overall survival (OS).
Of 123,684 patients included, 314 had ThySCC. ThySCC patients had a 5-year OS of 17.7%, more closely resembling ATC (8.3%) than PDTC or PTC. ThySCC and ATC patients had similar demographics, except ThySCC patients who were younger (68.0 vs. 70.2 years, p < 0.01). ThySCC tumors were smaller (mean 53.5 ± 45.7 vs. 69.5 ± 75.2 mm) with less frequent extrathyroidal extension (ETE) (64.0% vs. 73.8%), lymphovascular invasion (8.3% vs. 12.3%), and positive margins (22.0% vs. 28.3%) compared to ATCs (p < 0.05). ETE [HR 3.1 (95% CI 1.5-6.4), p < 0.05] and lymph node metastases [HR 2.2 (95% CI 1.2-4.0) p < 0.05] were independently associated with worse OS for ThySCC patients. Both ThySCC and ATC patients had similar surgical success rates, with R1 resection possible in 37.3% versus 35.0% of patients, respectively (p < 0.05). However, in contrast to ATC patients, adjuvant therapy was not associated with improved OS for ThySCC patients after complete resection.
ThySCC has a poor prognosis, similar to ATC, but with fewer aggressive features and no apparent survival benefit with adjuvant therapy after complete macroscopic surgical resection.
甲状腺原发性鳞状细胞癌(ThySCC)是一种罕见的癌症,主要仅在病例报告中有所描述。我们旨在描述ThySCC的预后,并将其肿瘤学行为与其他甲状腺恶性肿瘤进行比较。
查询国家癌症数据库,以识别2004年至2015年期间接受治疗的ThySCC、乳头状、高细胞变体、低分化(PDTC)和间变性(ATC)亚型甲状腺癌患者。按肿瘤类型比较人口统计学、肿瘤特征和治疗方法,并进行评估以确定总生存期(OS)的独立预测因素。
在纳入的123,684例患者中,314例患有ThySCC。ThySCC患者的5年总生存率为17.7%,与ATC(8.3%)更为相似,而不是PDTC或PTC。ThySCC和ATC患者的人口统计学特征相似,但ThySCC患者更年轻(68.0岁对70.2岁,p<0.01)。与ATC相比,ThySCC肿瘤更小(平均53.5±45.7对69.5±75.2mm),甲状腺外侵犯(ETE)频率更低(64.0%对73.8%),淋巴管侵犯(8.3%对12.3%),切缘阳性率更低(22.0%对28.3%)(p<0.05)。ETE[风险比(HR)3.1(95%置信区间1.5-6.4),p<0.05]和淋巴结转移[HR 2.2(95%置信区间1.2-4.0),p<0.05]与ThySCC患者较差的OS独立相关。ThySCC和ATC患者的手术成功率相似,分别有37.3%和35.0%的患者可能进行R1切除(p<0.05)。然而,与ATC患者不同,辅助治疗与ThySCC患者完全切除后的OS改善无关。
ThySCC预后较差,与ATC相似,但侵袭性特征较少,在肉眼完全手术切除后辅助治疗无明显生存获益。